Nephrotoxicity with Vancomycin in the Pediatric Population: A Systematic Review and Meta-Analysis
Vancomycin is frequently used to treat methicillin-resistant Staphylococcus aureus (MRSA) infections in pediatric patients. Vancomycin exposure may lead to an increase in frequency of nephrotoxicity. Our aim was to conduct a systematic review to describe predictors of nephrotoxicity associated with vancomycin, including documented trough concentrations ≥15mg/L. We also aimed to use a meta-analysis to assess the impact of a vancomycin trough ≥15 mg/L on nephrotoxicity.Methods:
A literature search was performed using PubMed, Cochrane Library, Embase, and Web of Sciences database. We included randomized clinical trials and observational studies evaluating the relationship between vancomycin troughs and nephrotoxicity in pediatric-aged patients. Studies not measuring troughs, or defining a different cut-off point than 15 mg/L, were excluded. Data on age, exclusion criteria, nephrotoxicity definition, risk factors for nephrotoxicity, and vancomycin trough levels were extracted from selected papers.Results:
Ten studies were identified for meta-analysis. All subjects had comparatively normal baseline serum creatinine values. Common risk factors identified included elevated (≥ 15mg/L) trough levels, renal impairment, hypovolemia, and concurrent use of nephrotoxic medications. Troughs ≥ 15mg/L increased nephrotoxicity by 2.7-fold (OR 2.71, 95% CI 1.82-4.05; I2= 40%, Q=0.09). These odds were further increased among patients in the pediatric intensive care unit (OR 3.61, 95% CI 1.21-10.74; I2=45%, Q=0.18).Conclusions:
Though the rate of vancomycin-induced nephrotoxicity is increased in pediatric patients with higher vancomycin troughs, other factors such as intensive care unit admission, hypovolemia, and concurrent nephrotoxic drug use appear to contribute to the development of nephrotoxicity.